Device Trial Radar · NCT07057817
The ACHILLS Trial; Application of Cerament in Heel Infection for Lower Limb Salvage
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jul 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Royal College of Surgeons, IrelandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ACHILLS Trial is a multicentre randomised controlled feasibility study comparing partial calcanectomy with and without the use of an antibiotic-impregnated bone graft substitute (Cerament G) for treating calcaneal osteomyelitis, specifically on wound healing rates, re-infection, and overall efficacy in a sample of 30 patients over a one-year period.
Conditions
- Osteomyelitis
- Diabetes
- Calcanectomy
Interventions
Cerament GDevice
Partial Calcanectomy plus cerament G
Standard Surgical ManagmentOther
Partial Calcanectomy as standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Wound HealingTime frame: 1 months post-surgery
- Rate of Wound HealingTime frame: 3 months post-surgery
- Rate of Wound HealingTime frame: 6 months post-surgery
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Galway
Galway, Ireland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.